The lack of details about which countries are involved and which companies will be impacted as a result of the new trade deal announcements reflects ongoing uncertainty.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

CHICAGO — CagriSema, a new weekly injection from Novo Nordisk combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, significantly reduced weight and improved ...

CagriSema delivers significant weight loss: In the REDEFINE 1 trial, Novo Nordisk’s CagriSema achieved a 22.7% mean weight reduction in adults with obesity or overweight without diabetes. Over half ...

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22, 2025 /PRNewswire/ -- Findings from two studies ...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine ...

Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type ...